课题基金 / 基金详情

GLOMERULAR CAPILLARY WALL--NORMAL AND PATHOLOGIC

GLOMERULAR CAPILLARY WALL--NORMAL AND PATHOLOGIC
肾小球毛细血管壁——正常和病理
批准号:
2905255
负责人:
Yashpal S. Kanwar
金额:
$30.0万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-04-01 至 2003-08-31

项目摘要

项目成果

Yashpal S. Kanwar的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Adapted from Investigator's Abstract): The overall objective of this proposal is to study the pathogenetic mechanisms involved in diabetic induced lesions in the embryonic metanephros. Three potential target genes will be examined mesodermal specific cDNA(MEST), H19, and TIN-Ag based on the spatio-temporal expression of these genes with MEST expressed in the metanephric mesenchyme H19 in the ureteric bud epithelia and TIN-Ag in an anti-polar proximal expression opposite that of H19 in the S-shaped body suggesting the three molecules are interlinked in early nephric development. Experiments are proposed under five specific aims to study the normal and abnormal biology of these molecules during renal development. I. Spatio-temporal expression of MEST, H19 and TIN-Ag during metanephric development will be investigated by using in situ hybridization, competitive PCR, immunohistochemical and immunoprecipitation methods. II. Their role in epithelial: mesenchymal interactions, prevalent during metanephrogenesis, will be assessed by antibody, antisense, transgene and transfection experiments. III. Molecular protein: protein and RNA: protein interactions will be investigated by using recombinant fusion proteins of various constructs of these three molecules. IV. Alterations in these molecules will be investigated during elevated concentration of glucose in vitro and in hyperglycemia. V. Finally, the hyperglycemia-induced/suppressed genes during embryonic renal development will be investigated using RDA and Serial Analysis of Gene Expression (SAGE).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathobiology of HMG-CoA reductase inhibitors in diabetes
Pathobiology of HMG-CoA reductase inhibitors in diabetes
Pathobiology of HMG-CoA reductase inhibitors in diabetes
Pathobiology of HMG-CoA reductase inhibitors in diabetes
海外基金